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Abstract
Background: Exercise training positively influences exercise tolerance and functional capacity of patients with
idiopathic pulmonary arterial hypertension (IPAH). However, the underlying mechanisms are unclear. We
hypothesized that exercise modulates the activated inflammatory state found in IPAH patients.
Methods: Single cardiopulmonary exercise testing was performed in 16 IPAH patients and 10 healthy subjects.
Phenotypic characterization of peripheral blood mononuclear cells and circulating cytokines were assessed before,
directly after and 1 h after exercise.
Results: Before exercise testing, IPAH patients showed elevated Th2 lymphocytes, regulatory T lymphocytes, IL-6,
and TNF-alpha, whilst Th1/Th17 lymphocytes and IL-4 were reduced. In IPAH patients but not in healthy subject,
exercise caused an immediate relative decrease of Th17 lymphocytes and a sustained reduction of IL-1-beta and IL-
6. The higher the decrease of IL-6 the higher was the peak oxygen consumption of IPAH patients.
Conclusions: Exercise seems to be safe from an immune and inflammatory point of view in IPAH patients. Our
results demonstrate that exercise does not aggravate the inflammatory state and seems to elicit an immune-
modulating effect in IPAH patients.
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Background
Pulmonary arterial hypertension (PAH) is a devastating,
progressive vascular disease characterized by elevated
pulmonary vascular resistance and right heart failure.
Idiopathic PAH (IPAH) is diagnosed when no known
condition or exposure associated with PAH is detectable.
In pulmonary arteries of patients with IPAH a promin-
ent peri-vascular inflammation including tertiary (ec-
topic) lymphoid follicles was frequently observed next to
endothelial dysfunction, in-situ thrombosis, loss of small
vessels and occlusive vascular remodeling [18, 23, 24].
The local inflammatory process is accompanied by an
altered systemic inflammatory status (or vice versa).
Levels of circulating cytokines and inflammatory cells
were found to be altered in patients with IPAH [5, 12,
18, 22, 25]. Peripheral regulatory T lymphocytes and
interleukin (IL)-17 producing Th lymphocytes were
found to be increased and C-C chemokine receptor
(CCR) 6+ T lymphocytes depleted in peripheral blood
samples taken from IPAH patients [12, 18, 25]. Interest-
ingly, it has been shown that the chemokine receptors
CCR4 and CXCR3 distinguish two stable subsets of IL-
17-producing cells within the CCR6+ compartment,
wherein CCR6+/CCR4-/CXCR3+ cells produced IL-17
and INF-gamma (i.e. Th1/Th17) [1]. The emerging focus
on inflammation lends itself to a whole new approach in
understanding the disease and to a new perspective of
treating IPAH.
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Physical exercise has an anti-inflammatory effect in
chronic cardiovascular diseases by amelioration of
chronic inflammation [16, 20]. Contracting skeletal
muscle cells produce cytokines such as IL-1ra, IL-6 and
IL-10 [10]. Immune-modulation and down-regulation of
the chronic inflammation seem possible due to repeated
short-lasting alterations in cytokine levels by exercise
[10]. On the other hand pro-inflammatory cytokines di-
minish in the long term due to the reduction of the vis-
ceral fat mass [10]. In advanced cardiopulmonary
diseases such as IPAH, however, cachexia and physical
degeneration may be present. Patients with IPAH who
underwent supervised exercise training reached higher
levels of physical activity, had decreased fatigue severity,
showed improved 6-min walk distance (6MWD), cardio-
pulmonary function such as improved peak oxygen con-
sumption and patient-reported quality of life [6, 8, 9].
Thus, it is recommended to implement controlled
exercise training and rehabilitation in PAH patients’ care
taking [3, 8, 9, 11, 27]. However, the underlying mecha-
nisms leading to the improvement of symptoms, exer-
cise, and functional capacity are not clear [9].
In this study, we present the first evidence for an
exercise-induced immune response in patients with
IPAH. The single bout of exercise in IPAH patients
seems to be safe from an immune and inflammatory
point of view and we demonstrate that the immune sys-
tem reacts differently in patients with IPAH as compared
to healthy control subjects.
Methods
Study subjects and procedure
Patients were recruited from the Center of Pulmonary
Arterial Hypertension at the University Medical Center
Hamburg-Eppendorf with the following inclusion
criteria: (1) prevalent diagnosis of IPAH in accordance
with the current diagnostic recommendations and
classification [9], (2) >18 years of age, (3) World Health
Organization functional class (WHO FC) II-III, (4) no
evidence for current or past malignant or autoimmune
diseases, (5) without exercise limitation due to an ortho-
pedic reason, and (6) without current infectious disease.
Healthy subjects underwent echocardiography to rule
out signs of right or left heart failure and were matched
with regard to age, gender and body mass index (BMI).
Cardiopulmonary exercise testing (CPET) was per-
formed as symptom-limited incremental cycling exercise
according to the ERS task force (2007) [17]. The rate of
workload increase was 10 Watt/min. The anaerobic
threshold (AT) was indirectly measured as the point
when the VCO2 −VO2 slope abruptly increases. The
peak oxygen consumption (Peak VO2/kg [ml/min/kg])
was used for analysis because it represents the most
widely used CPET parameter for therapeutic decision
making in PAH according to current recommendations
[9]. No interruption of drug intake was required and the
time between exercise testing and drug intake (PAH tar-
geted therapy) was 2–4 h. The following assessments
were obtained from all study subjects at the day of
CPET: 6MWD was obtained using a standardized proto-
col in accordance with the American Thoracic Society
statement (Measuring the distance patients can quickly
walk on a flat, hard surface 30 m hallway in a period of
6 min. Patients are allowed to stop and rest during
the test), functional class according to the modified
WHO classification was assessed by the attending
physician, N-terminal pro-hormone of brain natriuretic
peptide (NT-proBNP) concentrations were measured
using a commercially available assay (Dimension Vista,
Siemens Healthcare Diagnostics, IL, USA; Catalogue No.
K6423A), echocardiography and pulmonary function test
(PFT) including spirometry, body plethysmography and
gas dilution.
Differential white blood cell count and fluorescence-
activated cell sorting (FACS)
Peripheral venous whole blood samples were taken at
rest before, directly after and 1 h after CPET. Differential
blood count was obtained (Coulter Ac-T diff 2, Beck-
mann Coulter, Krefeld, Germany) for absolute and rela-
tive numbers of leukocytes, neutrophils, lymphocytes
and monocytes. Immunophenotyping was performed on
whole blood samples with multicolor (4–6 colors) flow
cytometry (LSR Fortessa, BD Bioscience, NJ, USA). In
brief, 100 μl blood samples were incubated with staining
buffer containing a pre-titrated concentration of fluores-
cent monoclonal antibodies or with immunoglobulin
(Ig) isotype-matched controls, respectively (all BioLe-
gend, CA, USA). Flurochromes were Alexa fluor 700
(anti-CD3), allophycocyanin (anti-CD8, -CD45, -CD127, -
CD183), brilliant Violet (BV) 421 (anti-TCRγδ), BV605
(anti-CD56), BV650 (anti-CD196), fluorescein isothio-
cyanate (anit-CD3, -CD14), pacific blue (anti-CD19), R-
phycoerythrin (anti-CD4, -CD16, -CD194) and peridinin-
chlorophyll-protein complex (anti-CD4). Compensation
has been performed computationally before analysis.
Erythrocytes were lysed (RBC Lysis/Fixation solution,
BioLegend, CA, USA), samples were washed twice with
buffer solution (phosphate-buffered saline, 0.1 % bovine
serum and 0.02 % NaN3), pelleted by centrifugation
(350 × g for 5 min) and stored in buffer solution in
the dark at 4 °C until analysis. Flow cytometric ana-
lysis was performed immediatly after blood sampling.
T and B lymphocytes were gated by expression of
CD3 or CD19 out of CD45+/CD16low/CD14− cells
(Table 1). T lymphocyte phenotypes were gated by size
exclusion, CD3+ and subsequent expression of CD4+/CD8−
(T helper), CD4−/CD8− (cytotoxic T) or CD4−/CD8−/TCRγδ+
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(TCRγδ) (Table 1). T helper lymphocytes were gated by
size exclusion, CD3+/CD4+ and subsequent expression of
surface chemokine receptors, which allowed for the dis-
tinction of four different memory T helper lymphocytes,
CXCR3+/CCR4−/CCR6− (Th1), CXCR3−/CCR4+/CCR6−
(Th2), CXCR3−/CCR4+/CCR6+ (Th17) and CXCR3+/
CCR4−/CCR6+ (Th1/Th17), as described previously
(Fig. 1 and Table 1) [1, 4]. Regulatory T lymphocytes
(Treg) were identified as T helper cells expressing high
levels of CD25 and low levels of CD127 (Table 1). Nat-
ural killer cells were gated by expression of CD45/
CD56 and subsequent expression of CD3 (Table 1). The
flow cytometry data were collected using FACS-Diva
software (BD Bioscience).
Enzyme linked immunosorbent assay (ELISA) and
magnetic bead-based multiplex immunoassay
Serum samples were stored at −80 °C and thawed only
for analyses. Serum concentrations of IL-6 and IL-17A
were measured using human IL-6 ELISA kit (Pierce
Table 1 Circulating peripheral blood mononuclear cells
quantified by flow cytometry
Tube Cell subset Immunophenotypes
Paternal cells Derivative cells
1 Natural killer T cells CD45+/CD56+ CD3+





2 T helper lymphocytes CD3+ CD4+/CD8−
Cytotoxic T lymphocytes CD4−/CD8+
TCRγδ lymphocytes CD4−/CD8−/TCRγδ+








4 Regulatory T lymphocytes CD3+/CD4+ CD25high/CD127low
CD cluster of differentiation, CCR C-C motif receptor, TCR T cell receptor, TH T
helper lymphocytes
Fig. 1 Fluorescence-activated cell sorting of T helper (H) lymphocytes (CD3+/CD4+): The surface marker CXCR3 and CCR4 differentiated four subsets
of TH lymphocytes after controlling for specificity of primary antibodies using the appropriate isotype control (a). CXCR3-/CCR4+ and CXCR3+/CCR4- TH
lymphocytes were characterised as CCR6+ or CCR6-, after controlling for specificity of primary antibody (b). APC = Allophycocyanin. BV = Brilliant Violet.
CD = Cluster of differentiation. CCR = Chemokine (C-C motif) receptor. CXCR = Chemokine (C-X-C motif) receptor. PE = R-Phycoerythrin
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Biotechnology, IL, USA) and Biosource IL-17 Cytoscreen
(Life Technologies, CA, USA) following the manufac-
turer’s instructions. ELISA standards and samples were
run in duplicate. The sensitivity of the assays was 1 pg/l
for IL-6 and 2 pg/l for IL-17A. The optical density
(450 nm) of each sample was determined using a micro-
plate reader (Sunrise, Männedorf, Switzerland). Serum
concentrations of IL-1-beta, IL-1ra, IL-2, IL-4, IL-10, IL-
12p70, IL-13 and TNF-alpha were analyzed using a mag-
netic bead-based multiplex assay solution (Bio-Plex Pro
TM Human Cytokine Standard 27-Plex Group I, Bio-
Rad Laboratories, CA, USA) according to manufacturer’s
protocol. In short, standards and samples were diluted
1:4 in buffer and added to microplates containing
assay beads in duplicate. The data were collected
using the Bio-Plex 200 suspension array system (Bio-
Rad Laboratories).
Statistical analysis
The differences between patients and healthy controls
were compared using the unpaired Student’s t test in
parametric data and the Chi-square-test in nominal data.
Correlations were assessed by Pearson’s coefficient. One-
way repeated measures analysis of variance (rANOVA)
was conducted to analyze the difference within patients
or healthy subjects, respectively, over time (i.e. before,
direct after and 1 h after CPET). Two-way repeated
measures rANOVA was conducted to analyze the differ-
ences between patients and healthy subjects over time.
P-values as result of rANOVA are presented following
Wilks’ Lambda. All reported p-values were two-sided
and considered significant at levels <0.05. All statistical
calculations were performed using SPSS statistics version
20 software (IBM, NY, USA).
Results
Baseline characteristics of study subjects
Hemodynamic parameters of 16 IPAH patients were
mean pulmonary arterial pressure (mPAP) of 51 ±
19 mm Hg, pulmonary vascular resistance (PVR) of
1065 ± 809 dyne*s*cm5, pulmonary artery wedge pres-
sure (PAWP) of 10 ± 3 mm Hg, right arterial pressure
(RAP) of 7 ± 5 mm Hg and cardiac index (CI) of 2.18 ±
0.6 L/min*m2. Mean time between right heart
catheterization and study inclusion was 18 ± 10 months.
At time of study, six IPAH patients were in WHO FC II
and 10 in WHO FC III. Fifteen patients were treated
with an endothelin-receptor antagonist (ERA), 14 pa-
tients with a phosphodiesterase type 5 inhibitor (PDE5-
I), 1 patient with a soluble guanylate cyclase stimulator
(sGC-S) and 3 patients with a prostacyclin analog. Only
one patient was treated with monotherapy and none of
the patients received long-term oxygen treatment.
Matching of healthy control subjects to patients with
IPAH was achieved for age, gender and BMI as intended.
All tested CPET parameters were significantly reduced
in IPAH patients compared to healthy control subjects.
FEV1 and FEV1/FVC were significantly decreased in
IPAH patients yet still within normal ranges. Levels of c-
reactive protein (CRP) were < 5 mg/dl in all study sub-
jects. Table 2 summarizes the baseline characteristics of
the study subjects.
Before exercise patients with IPAH showed a differing
composition of the T helper lymphocyte compartment
and altered levels of circulating cytokines
There was no significant difference in absolute levels of
leukocytes, lymphocytes, neutrophils and monocytes
before exercise between IPAH patients and control sub-
jects (Fig. 2). Within the CD4+ T helper lymphocyte
Table 2 Characteristics of patients with idiopathic pulmonary
arterial hypertension (IPAH) and healthy subjects
Parameter Groups P-value
IPAH Healthy subjects
n = 16 n = 10
Age [yr] 58 ± 16 58 ± 15 0.97
Gender female/male [n] 12/4 6/4 0.42a
BMI [kg/m2] 25 ± 6 24 ± 3 0.75
6MWD [m] 490 ± 100 638 ± 110 0.002
NT-proBNP [ng/l] 667 ± 594 68 ± 27 0.004
Cardiopulmonary exercise test (CPET)
Workload max [W] 73 ± 32 130 ± 46 0.005
Peak VO2/kg
[ml/min/kg]
15 ± 4 23 ± 5 0.001
Peak VO2 [l/min] 1.1 ± 0.4 1.7 ± 0.6 0.001
EqCO2 at AT
[l/min/l/min]
47 ± 7.6 32 ± 2.2 <0.001
VO2 at AT [l/min] 0.8 ± 0.2 1.2 ± 0.2 0.002
HR rest/max [/min] 78 ± 12/129 ± 28 77 ± 11/138 ± 18 0.90/0.35
BP systolic rest/max
[mm Hg]
102 ± 20/149 ± 30 118 ± 22/179 ± 22 0.06/0.01
BP diastolic rest/max
[mm Hg]
69 ± 12/80 ± 12 75 ± 10/81 ± 13 0.25/0.60
Pulmonary function test (PFT)
FEV1 % predicted [%] 78 ± 13 94 ± 8 0.002
FVC % predicted [%] 87 ± 13 95 ± 8 0.11
FEV1/FVC [%] 86 ± 11 102 ± 7 <0.001
DLCO % predicted [%] 76 ± 15 - -
Data are presented as mean ± SD or numbers. P-values are calculated by Stu-
dents’ t-test and aChi-Square-test. 6MWD 6-min walk distance, AT Anaerobic
threshold, BMI Body mass index, BP Blood pressure, EqCO2 Respiratory equiva-
lent for carbon dioxide, FEV1 Forced expiratory volume in 1 s, FVC Forced vital
capacity, HR Heart rate, IPAH Idiopathic pulmonary arterial hypertension, NT-
proBNP N-terminal prohormone of brain natriuretic peptide, VO2/kg Maximum
oxygen consumption per kilogram
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compartment patients with IPAH showed elevated sub-
sets of Th2 and regulatory T cells, while the subset of
Th1/Th17 lymphocytes was reduced as compared to
healthy subjects and as indicated by relative and absolute
cell counts (all p < 0.05; two-way rANOVA; Figs. 4 and
5). Prior to exercise, at rest, patients with IPAH demon-
strated elevated levels of IL-6 and TNF-alpha, whilst
level of IL-4 was reduced (all p < 0.05; two-way ANOVA;
Fig. 6).
Exercise caused a general increase in leukocytes and
lymphocytes
Overall, exercise provoked a significant, transient
elevation of absolute numbers of leukocytes, lympho-
cytes in patients with IPAH as well as in healthy
subjects (all p < 0.001; one-way rANOVA; Fig. 2a-b).
Given that no difference occurred between patients
and healthy subjects, two-way rANOVA revealed the
number of leukocytes and lymphocytes significantly
depended on relation to exercise (p < 0.001 and p =
0.005), but not on IPAH (p = 0.63 and p = 0.28). The
general increase of lymphocytes in patients with
IPAH and healthy was also found for T lymphocytes
(both p < 0.01; one-way rANOVA), and by a non-
significant trend for B lymphocytes, T helper lym-
phocytes and cytotoxic T lymphocytes (Fig. 3a-b and
e-f ). Interestingly, exercise led to a relative reduction
of B lymphocytes in healthy subjects but not in pa-
tients with IPAH (Fig. 3b-d). However, exercise did
not influence the level of TCR-γδ lymphocytes, nor
natural killer cells or natural killer T lymphocytes
(data not shown).
Exercise caused a relative reduction of Th17 lymphocytes
in patients with IPAH
Within the T helper lymphocyte compartment through-
out exercise no significant differences occurred regard-
ing the subsets of Th1, Th2, Th1/Th17 and regulatory T
lymphocytes comparing patients with IPAH and healthy
subjects (Figs. 4 and 5). Exercise, however, caused a rela-
tive reduction of Th17 lymphocytes in patients with
IPAH, but not in healthy subjects (p = 0.049; one-way
rANOVA; Fig. 4). However, the differences appeared to
be very small with significant overlap in standard devi-
ation and no differences were observed in regard of ab-
solute numbers of Th17 cells (Fig. 4).
Fig. 2 Exercise-induced changes of leukocytes, lymphocytes, neutrophils and monocytes: Exercise provoked significantly a transient elevation of
leukocytes and lymphocytes in patients with idiopathic pulmonary arterial hypertension (IPAH) and healthy subjects (a and b). No differences
occurred between groups. Whilst neutrophils and monocytes demonstrated only a non-significant trend towards a transients elevation (c and d).
#p < 0.05 (rANOVA)
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Exercise caused a reduction of IL-6 and IL-1-beta in pa-
tients with IPAH
Exercise caused a sustained reduction of the IL-6 level
in patients with IPAH but not in healthy subjects (p =
0.022; one-way rANOVA; Fig. 6a). Since healthy subjects
showed only a marginal increase in IL-6 following exer-
cise, two-way rANOVA revealed that the level of IL-6
significantly depended on IPAH (p = 0.009), but not on
relation to exercise (p = 0.094). In addition, the immedi-
ate and 1 h lasting reduction of the IL-6 level correlated
significantly with the peak VO2/kg in patients with IPAH
(p = 0.022 and p = 0.025; Fig. 7). Furthermore, exercise
caused a reduction of the IL-1-beta level in patients with
IPAH but not healthy subjects (p = 0.022; one-way
rANOVA; Fig. 6e). Herein, two-way rANOVA revealed
no significant dependence. The change of IL-6 and IL-1-
beta was not significantly related to the time to exhaus-
tion in the CPET and findings were not influenced by
change in hemoconcentration (data not shown). Exercise
did not influence differently the level of TNF-alpha, IL-
1ra, IL-12p70, IL-13 or IL-10 in patients with IPAH as
compared to healthy subjects (Fig. 6). The cytokines IL-
Fig. 3 Exercise-induced changes in lymphocyte subsets: Exercise caused a transient significant elevation of T lymphocytes in patients with
idiopathic pulmonary arterial hypertension (IPAH) and healthy subjects (a), but not in B lymphocytes (b). In the latter, however, exercise led to a
relative reduction in healthy subjects but in IPAH patients, which was not observed for absolute numbers of B lymphocytes (c and d). Exercise
provoked by a non-significant trend an elevation of CD4+/CD8- T helper and CD4-/CD8+ cytotoxic T lymphocytes in patients with IPAH and
healthy subjects (e and f). CD = Cluster of differentiation. §p < 0.05 (t-test); # p < 0.05 (rANOVA)
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Fig. 4 Exercise-induced changes of T helper (h) lymphocyte subsets: No significant alterations in regard of relative or absolute numbers of CXCR3+/CCR4-/
CCR6- (Th1) lymphocytes occurred (a and b). Prior to exercise patients with idiopathic pulmonary arterial hypertension (IPAH) showed significantly elevated
relative and absolute subsets of CXCR3-/CCR4+/CCR6- (Th2) cells (c and d) and significantly decreased levels of CXCR3+/CCR4-/CCR6+ (Th1/Th17) cells (g
and h) as compared to healthy subjects. Exercise did not significantly change these subsets (c, d, g and h). However, exercise induced a relative but not
absolute transients reduction of CXCR3-/CCR4+/CCR6+ (Th17) lymphocytes in patients with IPAH (e and f). CCR = Chemokine (C-C motif)
receptor. CXCR = Chemokine (C-X-C motif) receptor. *p < 0.05 (rANOVA); **p < 0.01 (rANOVA); #p < 0.05 (rANOVA)
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17 and IL-2 were detectable in only 1 out of 16 patients
with IPAH, respectively.
Discussion
The development of a chronic systemic inflammatory
state has been demonstrated repeatedly in patients with
IPAH. This inflammatory state is indicated by elevated
levels of circulating inflammation markers, such as IL-6,
and altered composition of peripheral blood mono-
nuclear cells (PBMC), such as regulatory T lymphocytes
or CCR6+ T lymphocytes [5, 18, 22, 25]. In accordance,
we found, prior to exercise, an elevated level of IL-6 and
altered composition of the CD4+ T lymphocyte subsets
in the peripheral blood of patients with IPAH. Within
the CD4+ T lymphocyte compartment Th1/Th17 lym-
phocytes were depleted in blood samples from patients
with IPAH and Th2 as well as Treg lymphocytes were el-
evated. While Th17 lymphocytes were not altered prior
to exercise.
The depletion of the CXCR3+/CCR4−/CCR6+ (Th1/
Th17) together with the observed increased expression
of CCL20, the ligand of CCR6, in lungs explanted from
patients with IPAH provide some evidence of the re-
cruitment of specific T helper lymphocytes to IPAH
lungs [18]. The CXCL10, ligand of CXCR3, was also
found to be elevated in IPAH lungs and blood samples,
which might favor the recruitment of CXCR3+ effector
T cells [13, 28]. These inflammatory processes might
therefore be inextricably linked to a specific (presumably
a Th1/Th17-predominant) (peri-) vascular inflammation
found in IPAH.
According to our data, exercise seemed to elicit a
specific modulation of the circulating T lymphocyte sub-
sets in patients with IPAH, a modulation of the chronic
systemic inflammatory state. Exercise may shift the
imbalance of the inflammatory status towards equilib-
rium or excess of the anti-inflammatory (or immune-
regulatory) activity. A single bout of cycling exercise
caused an immediate relative decrease of Th17 lympho-
cytes in patients compared to healthy subjects. However,
the effect was small-sized and prior to exercise no differ-
ences in Th17 levels were observed. An increased Th17
immune polarization as part of the dysregulated immune
response in patients with IPAH has recently been demon-
strated [12]. This study further substantiate autoimmunity
as contribution to the development or progression of
IPAH [12].
Environmental stress such as exercise could induce a
redistribution of T lymphocytes within lymphoid and
non-lymphoid organs. A uniform response pattern
seems to exist with a decrease in lymphocyte numbers
in the spleen, accompanied by an increase in lymphocyte
numbers in the lung, bone marrow and Peyer’s patches
[2, 15, 26]. Accordingly, we observed a transient increase
in the circulating lymphocyte numbers and also
leukocyte numbers following exercise. The distribution
of circulating lymphocytes is tightly controlled by their
ability to interact with endothelial cells at different ana-
tomical sites, which enables cell trafficking and defines
the kinetics of immune regulation [15]. Exercise might
alter the site- and disease-specific repertoire of adhesion
molecules on lymphocytes and, on the other hand, the
expression of corresponding ligands on endothelial cells.
This might be elicited by exercise-induced alterations in
circulating cytokine levels [14, 19, 29]. Moderate exercise
might, for instance, result in a Th1/Th2 imbalance in
favor of Th1 in healthy subjects [29]. Moreover, the
addition of lymphocytes from the marginated pool into
the circulation in response to exercise may influence
lymphocyte redistribution by itself, since the mobilized
cells may have different functional abilities compared to
those already in the circulation [26]. However, redistri-
bution of lymphocytes has mostly been demonstrated
for multiple exercise training or endurance exercise
Fig. 5 Exercise-induced changes of regulatory T helper lymphocytes: Prior to exercise relative, but not absolute, level of CD25high/CD127low (T
regs) were significantly elevated in patients with idiopathic pulmonary arterial hypertension (IPAH) as compared to healthy subjects (a and b).
Exercise, however, elicited no significant effect. CD = Cluster of differentiation. *p < 0.05 (rANOVA)
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Fig. 6 Exercise-induced changes of circulating cytokines: Prior to exercise patients with idiopathic pulmonary arterial hypertension (IPAH) showed
significantly elevated levels of interleukin (IL)-6 (a) and tumor necrosis factor (TNF)-alpha (b), whilst level of IL-4 (c) were significantly reduced as compared
to healthy subjects. No significant differences, occurred regarding IL-1ra (d), IL-1-beta (e), IL-12 (f), IL-13 (g) or IL-10 (h). Exercise caused a sustained reduction of
the IL-6 and IL-1-beta level in IPAH patients (rANOVA; a and e). *p<0.05 (rANOVA); **p<0.01 (rANOVA); #p<0.05 (rANOVA)
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protocols. Another mechanism for the modulation of
lymphocyte populations might be the differentiation of
lymphocytes. A rapid modulation following single exer-
cise training might result from an (trans-) differentiation
of lymphocyte from precursor cells, which could be me-
diated by circulating cytokines.
A high level of the cytokine IL-6 (4th quartile),
amongst other cytokines such as IL-2, IL-8, IL-10, and
IL-12p70, were associated with poor overall survival in
patients with IPAH or hereditary PAH (HPAH) [22]. The
systemic inflammatory response may reflect disease activity.
We observed a sustained reduction of circulating IL-1-beta
and IL-6 following exercise in patients with IPAH. In con-
trary to this finding several studies have reported an
exercise-induced release of IL-6 by contracting muscle cells
in health and disease state. It is believed that the exercise-
induced secretion of IL-6 to be a transcriptional event in
skeletal muscle cells and was observed to be depended on
exercise intensity and duration [7]. However, since exercise
duration was short in our study, this mechanism was un-
likely to influence post-exercise level of IL-6 in patients
with IPAH. Thus further mechanisms such as internaliza-
tion following receptor binding (e.g. in the process of
lymphocyte differentiation or in endothelial cells) might ac-
count for the observed reduction. Furthermore, we cannot
rule out that pharmacological treatment influences the
exercise-induced IL-6 response, since all patients were on
PAH targeted drugs. An influence of drug intake such as
indomethacin on exercise-induced IL-6 response has been
shown previously [7]. IL-6 has been linked to the pathogen-
esis of PAH. Administration of IL-6 is sufficient to cause
pulmonary vascular remodeling in rodents and its over-
expression spontaneously caused experimental pulmonary
hypertension (PH) [21]. Less is known in regard of the
pathogenic role of IL-1-beta in the setting of IPAH. The
level seemed to be elevated in patients with IPAH or
HPAH, but was not associated with survival [21, 22].
With the present explorative study, we looked into
short-term, immediate effects of exercise on the systemic
inflammatory state in a limited number of patients with
IPAH. The relative small sample size, the short-term
measuring points and the lack of bioelectrical indices
such as visceral fat percentage are limitations to the
study. With regard to a long-term effect it would be of
great interest to evaluate the effect of a controlled, su-
pervised training on the systemic inflammatory state in
patients with (I)PAH. Our results provide first evidence
for further investigations of this topic.
Conclusion
We demonstrate a link between the immune system and
physical exercise in patients with IPAH. Exercise seems
to elicit a modulation or redistribution of the circulating
T lymphocyte subsets and an amelioration of the altered
circulating cytokine profile in patients with IPAH, and
does not aggravate the inflammatory state. The single
bout of exercise in IPAH patients seems to be safe from
an immune and inflammatory point of view.
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function test; PH: Pulmonary hypertension; PVR: Pulmonary vascular
resistance; rANOVA: Repeated analysis of variances; RAP: Right atrial pressure;
sGC-S: Soluble guanylate cyclase stimulator; TCR: T cell receptor; Th: T helper;
TNF: Tumor necrosis factor; WHO-FC: World Health Organization functional class
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